Ariad Narrows Geographic Reach To Maximize Commercial Resources
This article was originally published in The Pink Sheet Daily
The biotech has been streamlining its operations through licensing deals and changing its R&D strategy to better reflect its new geographic makeup – moves that could make it attractive to buyers.
You may also be interested in...
After almost 20 years, targeted therapy for oncology is still producing breakthroughs. This week saw two breakthrough-designated novel kinase inhibitor approvals, Novartis' Rydapt (midostaurin) and Takeda's Alunbrig (brigatinib), and breakthrough status for Pfizer's next-generation candidate lorlatinib.
Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
In retrospect, the European Society for Medical Oncology meeting was a showcase for pivotal trial data included in a burst of targeted therapy new drug applications, and more drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto
The latest drug development news and highlights from our FDA Performance Tracker.